IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0242 | -8.64285714286 | 0.28 | 0.285 | 0.2433 | 482503 | 0.26375582 | CS |
4 | -0.0362 | -12.397260274 | 0.292 | 0.385 | 0.2433 | 819919 | 0.31043218 | CS |
12 | -0.0751 | -22.6956784527 | 0.3309 | 0.41 | 0.2303 | 686672 | 0.30897472 | CS |
26 | -0.5727 | -69.1249245625 | 0.8285 | 0.8587 | 0.217 | 853685 | 0.37127473 | CS |
52 | -1.1342 | -81.5971223022 | 1.39 | 1.74 | 0.217 | 602640 | 0.59546115 | CS |
156 | -2.7042 | -91.3581081081 | 2.96 | 4.9799 | 0.217 | 713484 | 1.99204274 | CS |
260 | -9.7442 | -97.442 | 10 | 10.319 | 0.217 | 616486 | 2.04999455 | CS |
Symbole | Prix | Vol. |
---|---|---|
TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 731,1M |
NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,5M |
RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 341,8M |
CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 237,15M |
BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,44M |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales